Tetrahydrofolic acid

From NuGOwiki

(Redirected from HMDB01846)
Jump to: navigation, search

The NuGOwiki Metabolite Database is a joint initiative of NuGO and HMDB

Taxonomy Navigation Box; search by

All Metabolites | Biochemical | Nutritional | Functional | Metabolic Pathways | Diseases | Phenotypes | Physiological Processes | Protein

Tetrahydrofolic acid
2D structure for Tetrahydrofolic acid
Chemical Name 2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
Chemical Formula C19H23N7O6
CAS Number 135-16-0
Chemical Information HMDB01846
Biochemical Taxonomy

  • Pterins

Functional Taxonomy

  • Coenzyme
  • DNA Component

Nutritional Taxonomy Not Available
Metabolic Pathways Not Available
Biofluid Location

  • Blood

Tissue Location

  • Erythrocyte
  • Fibroblasts
  • Intestine
  • Kidney
  • Liver
  • Myelin
  • Neurons
  • Pancreas
  • Placenta
  • Platelet
  • Prostate
  • Stratum Corneum
  • Testis
  • Brain

Normal Biofluid Concentrations

  • Blood: 0.0025 +/- 0.0044 umol/L

Normal Tissue Concentrations Not Available
Diseases / Conditions Related to Nutrition Not Available
Other (Monogenic Disorders)

Abnormal Biofluid Concentrations Not Available
Abnormal Tissue Concentrations Not Available
Physiological Processes Not Available
Authors:
Affiliations:

Contents

Introduction

guidelines
Tetrahydrofolate is a soluble coenzyme (vitamin B11 (in France, Germany and USA sometimes vitamin B9)) that is synthesized de novo by plants and microorganisms, and absorbed from the diet by animals. It is composed of three distinct parts: a pterin ring, a p-ABA (p-aminobenzoic acid) and a polyglutamate chain with a number of residues varying between 1 and 8. Only the tetra-reduced form of the molecule serves as a coenzyme for C1 transfer reactions. In biological systems, the C1-units exist under various oxidation states and the different tetrahydrofolate derivatives constitute a family of related molecules named indistinctly under the generic term folate. (PMID 16042593) Folate is important for cells and tissues that rapidly divide. Cancer cells divide rapidly, and drugs that interfere with folate metabolism are used to treat cancer. Methotrexate is a drug often used to treat cancer because it inhibits the production of the active form, tetrahydrofolate. Unfortunately, methotrexate can be toxic, producing side effects such as inflammation in the digestive tract that make it difficult to eat normally. -- Wikipedia; Signs of folate deficiency are often subtle. Diarrhea, loss of appetite, and weight loss can occur. Additional signs are weakness, sore tongue, headaches, heart palpitations, irritability, and behavioral disorders. Women with folate deficiency who become pregnant are more likely to give birth to low birth weight and premature infants, and infants with neural tube defects. In adults, anemia is a sign of advanced folate deficiency. In infants and children, folate deficiency can slow growth rate. Some of these symptoms can also result from a variety of medical conditions other than folate deficiency. It is important to have a physician evaluate these symptoms so that appropriate medical care can be given. -- Wikipedia; Folinic acid is a form of folate that can help 'rescue' or reverse the toxic effects of methotrexate. Folinic acid is not the same as folic acid. Folic acid supplements have little established role in cancer chemotherapy. There have been cases of severe adverse effects of accidental substitution of folic acid for folinic acid in patients receiving methotrexate cancer chemotherapy. It is important for anyone receiving methotrexate to follow medical advice on the use of folic or folinic acid supplements. -- Wikipedia Low concentrations of folate, vitamin B12, or vitamin B6 may increase the level of homocysteine, an amino acid normally found in blood. There is evidence that an elevated homocysteine level is an independent risk factor for heart disease and stroke. The evidence suggests that high levels of homocysteine may damage coronary arteries or make it easier for blood clotting cells called platelets to clump together and form a clot. However, there is currently no evidence available to suggest that lowering homocysteine with vitamins will reduce your risk of heart disease. Clinical intervention trials are needed to determine whether supplementation with folic acid, vitamin B12 or vitamin B6 can lower your risk of developing coronary heart disease. -- Wikipedia

Biological Function

guidelines

Catabolism

guidelines

Diseases / Conditions Related to Nutrition

guidelines


Other (Monogenic) Disorders

guidelines

Nutritional Information

guidelines

Drivers for biological variation

guidelines

Vulnerable groups

guidelines

Other resources

guidelines

Links

guidelines